These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience. Danese S; Colombel JF; Reinisch W; Rutgeerts PJ Aliment Pharmacol Ther; 2011 Apr; 33(8):857-69. PubMed ID: 21320139 [TBL] [Abstract][Full Text] [Related]
23. Stromelysin-1 and macrophage metalloelastase expression in the intestinal mucosa of Crohn's disease patients treated with infliximab. Di Sabatino A; Saarialho-Kere U; Buckley MG; Gordon JN; Biancheri P; Rovedatti L; Corazza GR; Macdonald TT; Pender SL Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1049-55. PubMed ID: 19357521 [TBL] [Abstract][Full Text] [Related]
24. Infliximab therapy in children with Crohn's disease: a one-year evaluation of efficacy comparing 'top-down' and 'step-up' strategies. Kim MJ; Lee JS; Lee JH; Kim JY; Choe YH Acta Paediatr; 2011 Mar; 100(3):451-5. PubMed ID: 20626362 [TBL] [Abstract][Full Text] [Related]
25. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Candon S; Mosca A; Ruemmele F; Goulet O; Chatenoud L; Cézard JP Clin Immunol; 2006 Jan; 118(1):11-9. PubMed ID: 16125467 [TBL] [Abstract][Full Text] [Related]
27. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. Chaparro M; Panes J; García V; Mañosa M; Esteve M; Merino O; Andreu M; Gutierrez A; Gomollón F; Cabriada JL; Montoro MA; Mendoza JL; Nos P; Gisbert JP J Clin Gastroenterol; 2011 Feb; 45(2):113-8. PubMed ID: 21242747 [TBL] [Abstract][Full Text] [Related]
28. Biologic therapy in Crohn's disease: review of the evidence. Loftus EV Rev Gastroenterol Disord; 2007; 7 Suppl 1():S3-12. PubMed ID: 17392631 [TBL] [Abstract][Full Text] [Related]
29. Increased plasma ghrelin following infliximab in Crohn's disease. Sung EZ; Da Silva NF; Goodyear S; McTernan PG; Sanger GJ; Nwokolo CU Aliment Pharmacol Ther; 2009 Jan; 29(1):83-9. PubMed ID: 18793341 [TBL] [Abstract][Full Text] [Related]
30. Scheduled maintenance therapy with infliximab improves the prognosis of Crohn's disease: a single center prospective cohort study in Japan. Takahashi S; Takagi S; Shiga H; Umemura K; Endo K; Kakuta Y; Takahashi S; Kinouchi Y; Shimosegawa T Tohoku J Exp Med; 2010 Mar; 220(3):207-15. PubMed ID: 20208416 [TBL] [Abstract][Full Text] [Related]
31. Orofacial granulomatosis as first manifestation of Crohn's disease: successful treatment of both conditions with a combination of infliximab and dapsone. Kemmler N; Pfannschmidt N; Strohal R Acta Derm Venereol; 2012 Jul; 92(4):406-7. PubMed ID: 22113308 [No Abstract] [Full Text] [Related]
32. Ineffectiveness of infliximab therapy in severe infantile Crohn's disease. Uslu N; Usta Y; Saltik-Temizel IN; Demir H; Gürakan F; Ozen H; Yüce A J Crohns Colitis; 2010 Feb; 4(1):106-9. PubMed ID: 21122492 [TBL] [Abstract][Full Text] [Related]
33. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Jürgens M; Mahachie John JM; Cleynen I; Schnitzler F; Fidder H; van Moerkercke W; Ballet V; Noman M; Hoffman I; van Assche G; Rutgeerts PJ; van Steen K; Vermeire S Clin Gastroenterol Hepatol; 2011 May; 9(5):421-7.e1. PubMed ID: 21334460 [TBL] [Abstract][Full Text] [Related]
34. Secondary amyloidosis in a patient with long duration Crohn's disease treated with infliximab. Fidalgo C; Calado J; Cravo M BioDrugs; 2010 Dec; 24 Suppl 1():15-7. PubMed ID: 21175229 [TBL] [Abstract][Full Text] [Related]
35. [Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn disease. A survey of a Cochrane review]. Al-Subeihe I; Nielsen OH Ugeskr Laeger; 2008 Dec; 170(50):4130-4. PubMed ID: 19091193 [No Abstract] [Full Text] [Related]
36. Rheumatic fever in a patient receiving infliximab therapy for Crohn disease. Abu-El-Haija M; Stasheff S; Atkins DL; Bishop WP J Pediatr Gastroenterol Nutr; 2011 Mar; 52(3):360-1. PubMed ID: 21150656 [No Abstract] [Full Text] [Related]
37. A Crohn's disease patient who does not respond to infliximab: what is next? Maharshak N; Plevy SE Clin Gastroenterol Hepatol; 2011 Dec; 9(12):1033-8. PubMed ID: 21699811 [No Abstract] [Full Text] [Related]
38. Infliximab (Remicade) and increased incidence of development of basal cell carcinoma. Gaines-Cardone E; Hale EK J Drugs Dermatol; 2012 May; 11(5):655-6. PubMed ID: 22527438 [TBL] [Abstract][Full Text] [Related]
39. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Sadowski DC; Bernstein CN; Bitton A; Croitoru K; Fedorak RN; Griffiths A; Can J Gastroenterol; 2009 Mar; 23(3):185-202. PubMed ID: 19319383 [TBL] [Abstract][Full Text] [Related]
40. Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy? Sorrentino D; Nash P; Viladomiu M; Hontecillas R; Bassaganya-Riera J Inflamm Bowel Dis; 2014 Apr; 20(4):757-66. PubMed ID: 24572206 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]